ArticleClinicoEconomics and outcomes research : CEOR2026
Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective.
Enrico Torre et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.